Azitra, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.33K shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 888.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 0.00 shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | -38.67K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | 1.33K shares 10-K · filed 2025-02-24 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2024-06-30 | -38.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 40.00K shares 10-Q · filed 2024-05-09 | |
| 2022-12-31 | 888.00 shares 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |